Healthcare entity
The clearest coverage concentration is market-trends: 4 of 5 stories, with the rest divided among 1 other category. The 122-day window averages about 0.3 stories each week. The busiest single day carried 2. Against the same-window beat baseline of 25% negative, this entity's 0% share is less negative.
Last mentioned: Jun 28, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 80 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The clearest coverage concentration is market-trends: 4 of 5 stories, with the rest divided among 1 other category. The 122-day window averages about 0.3 stories each week. The busiest single day carried 2. Against the same-window beat baseline of 25% negative, this entity's 0% share is less negative. Source depth averages 4.2 original sources per story, versus 3.5 across the same-window beat baseline. U.S. Food and Drug Administration is most often covered alongside CLR 125, which appears in 1 of these 5 stories. At 6.6, the average consequence score sits above the same-window beat average of 6.1. We currently track 5 Healthcare stories that mention U.S. Food and Drug Administration, published between March 5, 2026 and July 4, 2026.
Computed from the 5 stories linked to this entity, with beat comparisons drawn from all 563 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering U.S. Food and Drug Administration. Shared-story counts are live from our verified record — not editorial picks.
Potential EU Launch
Target window for commercial availability of iopofosine I 131 in Europe.
EMA Submission
Planned filing of Conditional Marketing Authorization for iopofosine I 131.
CLR 125 Data
Expected early data readout from Phase 1b study in triple-negative breast cancer.
JPM Q1 Earnings Report
JPMorgan Chase reports first-quarter financial results amidst regulatory and legal scrutiny.
FDA Orforglipron Decision
Expected regulatory ruling on Eli Lilly's oral GLP-1 candidate for weight loss.
Phase III Initiation
First patient dosed at Peking Union Medical College Hospital in China.
Earnings Release
Both companies report Q4 and FY 2025 financial results and business highlights.
Financial Results
Company reports 2025 results and provides corporate update.
FDA Partial Hold
FDA notifies PepGen of partial clinical hold on Freedom2 trial.
Regulatory Designations
FDA grants Fast Track and NMPA grants Breakthrough Therapy status.
Fiscal Year End
Cellectar completes a year of pipeline advancement and platform validation.
Phase II Data Publication
Results showing efficacy without hormonal side effects published in The Lancet.
The FDA authorized modified risk orders for ten ZYN nicotine pouch flavors, permitting claims that they reduce exposure to harmful chemicals. Health policymakers face new questions on harm reduction, youth appeal, and postmarket proof.
Source: Tajsabreen Ahamed (us) · Rttnews
Hope Medicine Inc. has initiated Phase III dosing for HMI-115, the first non-hormonal monoclonal antibody for endometriosis to reach this clinical stage. This milestone, supported by FDA Fast Track and NMPA Breakthrough designations, signals a potential shift away from traditional hormone-suppressing therapies in women's health.
Source: Woonsocketcall · Laotian Times
Investors are monitoring two critical mid-April deadlines: the FDA's decision on Eli Lilly's oral weight-loss drug, orforglipron, and JPMorgan Chase's first-quarter earnings report. These events serve as key indicators for the pharmaceutical sector's obesity market expansion and the banking sector's regulatory resilience.
Source: Adria Cimino (us) · fool.com
OmniAb and PepGen reported full-year 2025 results, highlighting a divergence between platform-based stability and clinical-stage volatility. While OmniAb expanded its royalty-bearing portfolio, PepGen faced a significant setback with a partial FDA clinical hold on its Freedom2 trial.
Source: pharmiweb.com · pharmiweb.com
Cellectar Biosciences has announced its 2025 year-end results, highlighting a strategic shift toward European commercialization for its lead radiotherapeutic, iopofosine I 131. The company remains on track for a Q3 2026 regulatory submission to the EMA, while simultaneously advancing its Phase 1b study for CLR 125 in triple-negative breast cancer.
Source: The Manila Times · Benzinga
U.S. Food and Drug Administration is linked from 5 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
